SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1527 7755 "

Sökning: L773:1527 7755

  • Resultat 21-30 av 582
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Arriagada, Rodrigo, et al. (författare)
  • Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer.
  • 2010
  • Ingår i: Journal of clinical oncology. - 1527-7755. ; 28:1, s. 35-42
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE Based on 5-year or shorter-term follow-up data in recent randomized trials, adjuvant cisplatin-based chemotherapy is now generally recommended after complete surgical resection for patients with non-small-cell lung cancer (NSCLC). We evaluated the results of the International Adjuvant Lung Cancer Trial study with three additional years of follow-up. PATIENTS AND METHODS Patients with completely resected NSCLC were randomly assigned to three or four cycles of cisplatin-based chemotherapy or to observation. Cox models were used to evaluate treatment effect according to follow-up duration. Results The trial included 1,867 patients with a median follow-up of 7.5 years. Results showed a beneficial effect of adjuvant chemotherapy on overall survival (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.02; P = .10) and on disease-free survival (HR, 0.88; 95% CI, 0.78 to 0.98; P = .02). However, there was a significant difference between the results of overall survival before and after 5 years of follow-up (HR, 0.86; 95% CI, 0.76 to 0.97; P = .01 v HR, 1.45; 95% CI, 1.02 to 2.07; P = .04) with P = .006 for interaction. Similar results were observed for disease-free survival. The analysis of non-lung cancer deaths for the whole period showed an HR of 1.34 (95% CI, 0.99 to 1.81; P = .06). CONCLUSION These results confirm the significant efficacy of adjuvant chemotherapy at 5 years. The difference in results beyond 5 years of follow-up underscores the need for the long-term follow-up of other adjuvant lung cancer trials and for a better identification of patients deriving long-term benefit from adjuvant chemotherapy.
  •  
22.
  •  
23.
  •  
24.
  •  
25.
  •  
26.
  •  
27.
  • Ayas, Mouhab, et al. (författare)
  • Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.
  • 2013
  • Ingår i: Journal of Clinical Oncology. - 0732-183X .- 1527-7755. ; 31:13, s. 1669-76
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE Allogeneic hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi anemia (FA). Data on outcomes in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome (MDS), or acute leukemia have not been separately analyzed. PATIENTS AND METHODS We analyzed data on 113 patients with FA with cytogenetic abnormalities (n = 54), MDS (n = 45), or acute leukemia (n = 14) who were reported to the Center for International Blood and Marrow Transplant Research from 1985 to 2007. Results Neutrophil recovery occurred in 78% and 85% of patients at days 28 and 100, respectively. Day 100 cumulative incidences of acute graft-versus-host disease grades B to D and C to D were 26% (95% CI, 19% to 35%) and 12% (95% CI, 7% to 19%), respectively. Survival probabilities at 1, 3, and 5 years were 64% (95% CI, 55% to 73%), 58% (95% CI, 48% to 67%), and 55% (95% CI, 45% to 64%), respectively. In univariate analysis, younger age was associated with superior 5-year survival (≤ v > 14 years: 69% [95% CI, 57% to 80%] v 39% [95% CI, 26% to 53%], respectively; P = .001). In transplantations from HLA-matched related donors (n = 82), younger patients (≤ v > 14 years: 78% [95% CI, 64% to 90%] v 34% [95% CI, 20% to 50%], respectively; P < .001) and patients with cytogenetic abnormalities only versus MDS/acute leukemia (67% [95% CI, 52% to 81%] v 43% [95% CI, 27% to 59%], respectively; P = .03) had superior 5-year survival. CONCLUSION Our analysis indicates that long-term survival for patients with FA with cytogenetic abnormalities, MDS, or acute leukemia is achievable. Younger patients and recipients of HLA-matched related donor transplantations who have cytogenetic abnormalities only have the best survival.
  •  
28.
  • Baccarani, Michele, et al. (författare)
  • Chronic myeloid leukemia : an update of concepts and management recommendations of European LeukemiaNet
  • 2009
  • Ingår i: Journal of Clinical Oncology. - 0732-183X .- 1527-7755. ; 27:35, s. 6041-6051
  • Forskningsöversikt (refereegranskat)abstract
    • PURPOSE: To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. METHODS: These recommendations are based on a critical and comprehensive review of the relevant papers up to February 2009 and the results of four consensus conferences held by the panel of experts appointed by ELN in 2008. RESULTS: Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure, and the response to second-generation TKIs was defined as suboptimal or failure. CONCLUSION: Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.
  •  
29.
  • Barbui, Tiziano, et al. (författare)
  • Philadelphia-Negative Classical Myeloproliferative Neoplasms : Critical Concepts and Management Recommendations From European LeukemiaNet
  • 2011
  • Ingår i: Journal of Clinical Oncology. - 0732-183X .- 1527-7755. ; 29:6, s. 761-770
  • Tidskriftsartikel (refereegranskat)abstract
    • We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first-and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.
  •  
30.
  • Bardi, G, et al. (författare)
  • Tumor karyotype predicts clinical outcome in colorectal cancer patients
  • 2004
  • Ingår i: Journal of Clinical Oncology. - 1527-7755. ; 22:13, s. 2623-2634
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose To investigate the prognostic value of the overall karyotypic features and specific chromosome aberrations in colorectal cancer (CRC). Patients and Methods Cytogenetic features of 150 primary CRCs investigated at the time of surgery were correlated with patient survival by univariate and multivariate analyses, using classical clinicopathologic parameters as covariates. Results In univariate analysis, in addition to tumor grade and clinical stage, structural aberrations as well as rearrangements of chromosomes 8 and 16 were significantly correlated with shorter overall survival. Karyotypic complexity, rearrangements of chromosomes 8 and 16, and loss of chromosome 4 were significantly correlated with shorter disease-free survival. In multivariate analysis, in addition to tumor grade, the type of chromosome aberrations (structural or numerical), ploidy, and loss of chromosome 18 came across as independent prognostic factors in the group of all patients. In the subset of patients with stage I and II carcinomas, none of the clinicopathologic variables could independently predict patient survival, whereas the presence of structural chromosomal aberrations was the only independent predictor of poor prognosis. In the subset of patients with stage III carcinomas, the presence of structural changes of chromosome 8 was a stronger independent predictor of prognosis than was tumor grade. Conclusion Cytogenetic tumor features are valuable predictors of prognosis in CRC patients. The tumor karyotype should therefore be taken into account in the clinical management of patients with this disease, especially for patients having cancers of the early or intermediate stages I, II, and III.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 582
Typ av publikation
tidskriftsartikel (485)
konferensbidrag (92)
forskningsöversikt (5)
Typ av innehåll
refereegranskat (410)
övrigt vetenskapligt/konstnärligt (172)
Författare/redaktör
Glimelius, Bengt (31)
Bergh, J (26)
Hall, P (17)
Czene, K (13)
Malmström, Per (11)
Bjorkholm, M (11)
visa fler...
Fernö, Mårten (10)
Holmberg, Lars (10)
Karlsson, Per, 1963 (9)
Landgren, O (9)
Kogner, P (8)
Lindblom, A (8)
Stattin, Pär (8)
Laurell, Anna (8)
Eriksson, Mikael (8)
Garmo, Hans (8)
Lindman, Henrik (8)
Jerkeman, Mats (7)
Lagergren, J (7)
Jonsson, B (7)
Hansson, J. (7)
Adolfsson, J. (7)
Lagergren, P (7)
Kristinsson, SY (7)
Tandstad, T (7)
Cunningham, David (7)
Lilja, Hans (6)
Dahl, Olav (6)
Eriksson, M (6)
Tabernero, Josep (6)
Cunningham, D (6)
Adami, Hans Olov (6)
Bergh, Jonas (6)
Van Cutsem, Eric (6)
Weiderpass, Elisabet ... (6)
Kimby, E (6)
Jirström, Karin (6)
Hemminki, Kari (6)
Cohn-Cedermark, G (6)
Harmenberg, U. (6)
Potschger, U (6)
Valteau-Couanet, D (6)
Castel, V (6)
Dickman, PW (6)
Derolf, AR (6)
Anderson, Harald (6)
Hellstrom-Lindberg, ... (6)
Helgadottir, H (6)
Cavallin-Ståhl, Eva (6)
Goldhirsch, Aron (6)
visa färre...
Lärosäte
Karolinska Institutet (367)
Uppsala universitet (143)
Lunds universitet (109)
Göteborgs universitet (57)
Umeå universitet (56)
Linköpings universitet (32)
visa fler...
Örebro universitet (17)
Kungliga Tekniska Högskolan (8)
Marie Cederschiöld högskola (7)
Högskolan i Gävle (2)
Stockholms universitet (1)
Handelshögskolan i Stockholm (1)
Linnéuniversitetet (1)
Högskolan Dalarna (1)
Blekinge Tekniska Högskola (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (582)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (295)
Samhällsvetenskap (2)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy